|
The following stocks are the leading risers and fallers on AIM on Monday. ---------- AIM - WINNERS ---------- Galileo Resources PLC, up 16% at 1.13p, 12-month range 0.65p-1.23p. The copper, gold and lithium mine developer in Zambia, Zimbabwe and Botswana says its prospecting licence PL253 in the Kalahari Copperbelt of Botswana has intersected a wide interval containing intermittent visible copper mineralisation. Drill samples will now be prepared for initial geochemical testing, and two further holes on a separate target are expected to complete ‘shortly’. ‘It is very pleasing that we have made an early copper intersection in our RC drilling programme on PL253 as we were essentially drilling a blind target based on soil geochemistry and geophysical interpretation of the geology,’ says Chief Executive Officer & Chair Colin Bird. ‘There is much recent interest in this northwestern part of the KCB and Galileo is well positioned in relation to the recognised prospective stratigraphy of the area.’ ---------- ValiRx PLC, up 12% at 0.73 pence, 12-month range 0.38p-2.37p. The Essex-based life sciences company receives a notice of allowance from the European Patent Office for ‘nanoparticle for anti-cancer peptides and uses thereof’, a key patent application for subsidiary Cytolytix Ltd. This follows the allowance of claims from its ‘polyleucine-based peptides as anti-cancer agents’ application, for which ValiRx has requested an accelerated examination. ‘In addition, we are rapidly progressing with the in-vitro and ex-vivo validation of the platform by leveraging the combined experience and resources of our tCRO, Inaphaea Biolabs, with the advanced non animal 3D-culture testing capabilities we have brought in through our capability partners,’ says Chief Executive Officer Mark Eccleston. ‘Development of triple negative breast cancer models on Screenin3D’s UpScale3Dlab-on-a-chip platform was a key strategic objective for ValiRx’s cytolytic peptide program through our partially owned subsidiary, Cytolytix. We are further extending these capabilities to include VoxCell’s proprietary fully perfusable vascularised 3D tissue culture models as we announced in July 2025. These advanced models are critical in assessing the cell killing efficacy of our oncolytic peptides as well as their potential to engage the host immune system. The potential immune boost feature of this class of therapeutics could significantly enhance both efficacy and durability of response.’ ---------- AIM - LOSERS ---------- Mkango Resources Ltd, down 7.3% at 38.00p, 12-month range 5.00p-46.89p. The Malawi-focused producer of recycled rare earth magnets, alloys, and oxides says pretax loss for the six months that ended June 30 widens to $3.7 million from $1.8 million the year before, as total expenses increase 53% to $2.6 million from $1.7 million. In the second quarter, pretax loss widens to $1.2 million from $694,934 the year before, driven largely by a $701,438 fair value adjustment relating to investor warrants, while second-quarter expenses double to $1.3 million from $662,035 a year earlier. Mkango continues to report no revenue. ‘The reporting period was dominated by the news of restrictions on the export of rare earths from China, and their subsequent consequences. While framed as a national-security measure, the restrictions were widely perceived as retaliation in response to higher tariffs imposed by the USA on China,’ says Mkango. ‘There was immediate fallout as a result of the restrictions. The scrutiny of Chinese customs officials slowed shipments, with magnet exports in April 2025 reported to be approximately 50% lower than the previous month. Later in the reporting period, China began granting licences and signalled selective easing for some companies in the supply chain, leading to a partial rebound in June magnet exports. Volumes, however, remained below 2024 levels.’ ---------- Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
